GlassScriptPhysician profile
Kathryn Jones
NPI 1235428418
$4,716.75
in general payments reported to CMS, 2019-2025
25 companies · $471 in 2025
The $471 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $94.71 · 2022: $204 · 2023: $206 · 2024: $3,393 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,570 · Food and Beverage: $1,402 · Travel and Lodging: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,569.99 |
| Food and Beverage | $1,402.49 |
| Travel and Lodging | $1,097.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,854.67 | 2024 | |
| Organon LLC | $352.49 | 2022-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $277.20 | 2020-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $142.89 | 2025 | |
| Abbvie INC. | $115.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.06 | 2019-2025 | |
| Sage Therapeutics, LLC | $105.77 | 2022-2025 | Zurzuvae |
| Pfizer INC. | $97.36 | 2019-2025 | |
| Hologic Sales and Service, LLC | $86.75 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Innovation Technologies INC | $76.39 | 2022-2025 | Irrisept |
| Genzyme Corporation | $71.88 | 2024 | |
| Roche Diagnostics Corporation | $65.23 | 2019 | |
| Exeltis, USA INC. | $59.28 | 2019-2025 | Slynd |
| Minerva Surgical, INC | $53.98 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $42.93 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $41.03 | 2025 | Gemtesa, Myfembree |
| Glaxosmithkline, LLC. | $36.66 | 2023 | Zejula |
| Mayne Pharma Commercial LLC | $17.58 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.26 | 2023 | Trulance |
| Coopersurgical, INC. | $15.89 | 2020 | |
| Janssen Biotech, INC. | $15.85 | 2024 | Stelara |
| Medtronic, INC. | $15.61 | 2024 | Truclear |
| Avion Pharmaceuticals | $14.62 | 2019 | |
| Allergan, INC. | $14.45 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.65 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.